Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Total 13F shares
-
55,533,332
-
Share change
-
-7,923,936
-
Total reported value
-
$48,315,841
-
Price per share
-
$0.8698
-
Number of holders
-
76
-
Value change
-
-$6,846,381
-
Number of buys
-
32
-
Number of sells
-
35
Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q2 2020
As of 30 Jun 2020 Lineage Cell Therapeutics, Inc. - Common shares (LCTX) had 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 55,533,332 shares of stock of the company.
Largest 10 holders included BROADWOOD CAPITAL INC, VANGUARD GROUP INC, Defender Capital, LLC., Prescott General Partners LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, JANE STREET GROUP, LLC, Russell Investments Group, Ltd., Northeast Financial Consultants Inc, and RENAISSANCE TECHNOLOGIES LLC.
This table shows 77 institutional shareholders of the security as of 30 Jun 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.